Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.50 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 4/20 | 0.49 |
| ▸ | IKBKB | O14920 | 3/20 | 0.49 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590765 | 0.91 | JAK2 (0.51) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14063782 | 0.91 | JAK2 (0.52) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14021327 | 0.90 | JAK2 (0.49) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14063781 | 0.90 | SYK (0.53) | PIK3CAPIK3CBPIK3CGJAK2JAK3 | |
| SCHEMBL8311018 | 0.89 | JAK2 (0.61) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14063828 | 0.89 | CAMK2D (0.61) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14063777 | 0.89 | JAK2 (0.49) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL14021629 | 0.89 | JAK2 (0.54) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL3049760 | 0.89 | SYK (0.51) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 | |
| SCHEMBL4063691 | 0.88 | JAK2 (0.52) | PIK3CAPIK3CBPIK3CGCAMK2DJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349840-B1 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442699-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429599-B2 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-09-30 | — | — | US | disclosed |
| US-7129242-B2 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-10-31 | — | — | US | disclosed |
| US-7122544-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060030576-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2006-02-09 | — | — | US | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | PIK3CA 2501/4885PIK3CB 2338/4885PIK3CG 3039/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | PIK3CA 21/4885PIK3CB 24/4885PIK3CG 34/4885 |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | MAPK6, MAP3K6, MAPK1 | PIK3CA 145/4885PIK3CB 149/4885PIK3CG 249/4885 |
| US-20060030576-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | PIK3CA 26/4885PIK3CB 35/4885PIK3CG 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.